Scarica l'app Stockscreener
8.69
5.95%
-0.55
Pre-mercato:
8.82
0.13
+1.50%
Precedente Chiudi:
$9.24
Aprire:
$9.35
Volume 24 ore:
735.89K
Relative Volume:
0.84
Capitalizzazione di mercato:
$439.91M
Reddito:
$89.04M
Utile/perdita netta:
$-241.08M
Rapporto P/E:
-1.6521
EPS:
-5.26
Flusso di cassa netto:
$-194.72M
1 W Prestazione:
+7.55%
1M Prestazione:
-19.98%
6M Prestazione:
-11.87%
1 anno Prestazione:
+46.79%
Intervallo 1D:
$8.59
$9.35
Intervallo di 1 settimana:
$8.08
$9.65
Portata 52W:
$5.035
$16.19
Regenxbio Inc Stock (RGNX) Company Profile
Nome
Regenxbio Inc
Settore
Industria
Telefono
240-552-8181
Indirizzo
9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD
Compare RGNX vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RGNX
Regenxbio Inc
|
8.69 | 467.76M | 89.04M | -241.08M | -194.72M | -5.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.27 | 123.47B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
766.66 | 83.60B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
748.72 | 46.83B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
318.65 | 43.11B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
297.04 | 34.79B | 5.36B | 287.73M | 924.18M | 2.5229 |
Regenxbio Inc Stock (RGNX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-28 | Ripresa | Barclays | Overweight |
| 2025-02-11 | Downgrade | Goldman | Buy → Neutral |
| 2025-02-07 | Ripresa | Raymond James | Outperform |
| 2024-11-15 | Ripresa | Morgan Stanley | Overweight |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-06-07 | Iniziato | Goldman | Buy |
| 2024-03-11 | Iniziato | H.C. Wainwright | Buy |
| 2024-03-08 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-03-06 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-02-21 | Ripresa | Raymond James | Outperform |
| 2023-11-01 | Iniziato | Stifel | Buy |
| 2023-06-02 | Iniziato | Robert W. Baird | Outperform |
| 2022-06-23 | Iniziato | Berenberg | Buy |
| 2021-12-15 | Iniziato | Wedbush | Neutral |
| 2021-10-19 | Ripresa | Morgan Stanley | Overweight |
| 2021-01-06 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2020-12-16 | Iniziato | UBS | Buy |
| 2020-06-25 | Ripresa | BofA/Merrill | Buy |
| 2020-05-13 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2019-08-20 | Aggiornamento | SVB Leerink | Underperform → Mkt Perform |
| 2019-06-18 | Reiterato | Chardan Capital Markets | Buy |
| 2019-06-14 | Ripresa | Raymond James | Outperform |
| 2019-06-05 | Reiterato | Chardan Capital Markets | Buy |
| 2019-02-25 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2019-02-05 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2018-12-17 | Reiterato | Chardan Capital Markets | Buy |
| 2018-11-08 | Reiterato | BofA/Merrill | Neutral |
| 2018-08-08 | Reiterato | Chardan Capital Markets | Buy |
| 2018-07-23 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2018-07-10 | Reiterato | Chardan Capital Markets | Buy |
| 2018-05-09 | Reiterato | Barclays | Overweight |
| 2018-04-09 | Reiterato | Chardan Capital Markets | Buy |
| 2018-03-12 | Downgrade | Evercore ISI | Outperform → In-line |
| 2018-02-13 | Iniziato | Mizuho | Neutral |
| 2017-11-09 | Ripresa | Morgan Stanley | Overweight |
Mostra tutto
Regenxbio Inc Borsa (RGNX) Ultime notizie
RGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire
Shareholders that lost money on REGENXBIO Inc.(RGNX) should contact The Gross Law Firm about pending Class ActionRGNX - PR Newswire
GSA Capital Partners LLP Has $100,000 Stock Holdings in REGENXBIO Inc. $RGNX - MarketBeat
REGENXBIO Stockholders Urged to Recover Losses - National Today
REGENXBIO, Inc. Stockholders Have RightsStockholders Who Lost Money Investing in RGNX Should Contact Robbins LLP for Information About Recovering Their Losses – Company Announcement - Financial Times
When a Clinical Hold Disrupts a Gene Therapy Program: What Happened to Regenxbio Stock - TipRanks
Bronstein, Gewirtz & Grossman LLC Urges REGENXBIO Inc. Investors to Act: Class Action Filed Alleging Investor Harm - GlobeNewswire
Biotech REGENXBIO schedules three March investor talks, with webcast access - Stock Titan
REGENXBIO to Participate in Upcoming Investor Conferences - Yahoo Finance Singapore
ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
REGENXBIO Inc. $RGNX Shares Purchased by JPMorgan Chase & Co. - MarketBeat
REGENXBIO Inc. (RGNX): Investor Outlook With A Promising 225% Upside Potential - DirectorsTalk Interviews
RegenXBio’s RGX-121 Hunter Syndrome Trial Faces Suspension: What Investors Should Know - TipRanks
RGNX SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds REGENXBIO (RGNX) Investors of Securities Class Action Deadline on April 14, 2026 – Company AnnouncementFT.com - Financial Times
Federal Circuit Revives REGENXBIO Gene Therapy Patent Suit Against Sarepta - Lawyer Monthly
RGNX SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds REGENXBIO (RGNX) Investors of Securities Class Action Deadline on April 14, 2026 - Sahm
Regenxbio Shares Face Significant Setback Following FDA Decision - AD HOC NEWS
REGENXBIO Inc. Sued for Securities Law ViolationsContact the DJS Law Group to Discuss Your RightsRGNX - marketscreener.com
RGNX Investors Have Opportunity to Lead REGENXBIO, Inc. Securities Fraud Lawsuit - PR Newswire
Responsive Playbooks and the RGNX Inflection - Stock Traders Daily
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against PayPal and REGENXBIO and Encourages Investors to Contact the Firm - The Daily Tribune News
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against PayPal and REGENXBIO and Encourages Investors to Contact the Firm - GlobeNewswire Inc.
ROSEN, LEADING INVESTOR COUNSEL, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
Class Action Filed Against REGENXBIO Inc. (RGNX)April 14, 2026 Deadline to Join – Contact ... - Bluefield Daily Telegraph
FDA Commissioner Refers To Rare Disease Drug With Associated Morbidity: Analysts Are Divided If Makary Meant Regenxbio Or Uniqure’s Experimental Therapy - Stocktwits
Regenxbio (RGNX) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Finviz
RGNX STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that REGENXBIO Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Portnoy Law Firm Announces Class Action on Behalf of REGENXBIO, Inc. Investors - marketscreener.com
Regenxbio (RGNX) Likely to Surpass Earnings Predictions: Will the Share Price Rise? - Bitget
Regenxbio dealt win by appeals court in patent spat with Sarepta - MSN
RGNX CLASS ACTION REMINDER: Faruqi & Faruqi, LLP Reminds - GlobeNewswire
Contact Levi & Korsinsky by April 14, 2026 Deadline to Join Class Action Against REGENXBIO Inc.(RGNX) - marketscreener.com
REGENXBIO to announce Q4 and full year 2025 results in March conference call - Traders Union
Trading Action: Why is REGENXBIO Inc stock going upWeekly Market Outlook & Capital Efficient Trade Techniques - baoquankhu1.vn
REGENXBIO to Host Conference Call on March 5 to Discuss Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights - The AI Journal
Biotech REGENXBIO lines up March 5 call on Q4 and 2025 results - Stock Titan
REGENXBIO (NASDAQ:RGNX) Shares Pass Below 50 Day Moving AverageHere's Why - MarketBeat
ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionRGNX - ACCESS Newswire
RGNX UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds REGENXBIO (RGNX) Investors of Securities Class Action Deadline on April 14, 2026 - marketscreener.com
Pomerantz Law Firm Reminds Investors with Losses on their Investment in REGENXBIO Inc. of Class Action Lawsuit and Upcoming Deadlines – RGNX - marketscreener.com
Stockholders Who Lost Money Investing in REGENXBIO, Inc. Should Contact Robbins LLP for Information About Leading the Class Action Against RGNX - ACCESS Newswire
2026-02-24 | Stockholders Who Lost Money Investing in REGENXBIO, Inc. Should Contact Robbins LLP for Information About Leading the Class Action Against RGNX | NDAQ:RGNX | Press Release - Stockhouse
US Fed Circuit protects 101 passage for some gene therapy patents - BioWorld MedTech
RGNX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that REGENXBIO Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 14, 2026 in REGENXBIO LawsuitRGNX - PR Newswire
Holzer & Holzer, LLC Reminds RGNX Investors of the April 14, 2026 Lead Plaintiff Deadline in the REGENXBIO Inc. Securities Class Action - marketscreener.com
Holzer & Holzer, LLC Reminds RGNX Investors of the April - GlobeNewswire
PATENT—Fed. Cir.: Federal Circuit revives lawsuit over muscular dystrophy treatment patent - VitalLaw.com
Contact Levi & Korsinsky by April 14, 2026 Deadline to Join Class Action Against REGENXBIO Inc. (RGNX) - GlobeNewswire
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before ... - Caledonian Record
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages REGENXBIO, Inc. - GlobeNewswire
Regenxbio Inc Azioni (RGNX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
5.71%
0.02%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):